36 completed, 1 terminated, 1 withdrawn. 11 Phase 3, 8 Phase 1, 4 Phase 4, 3 Phase 2.
By phase and status
Follow Growth Hormone Disorder: new trials by email Literature Review of Growth Hormone Disorder trials Research Report on Growth Hormone Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.
Somapacitan - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 1 | Completed | Novo Nordisk A/S | 34 | 2017-08-16 | 2019-05-24 |
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function
Somapacitan - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 1 | Completed | Novo Nordisk A/S | 44 | 2017-06-20 | 2020-04-17 |
A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency
somapacitan, Norditropin - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 3 | Completed | Novo Nordisk A/S | 62 | 2017-03-03 | 2020-11-23 |
Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
somapacitan, Norditropin® FlexPro® pen - Growth Hormone Disorder, Growth Hormone Deficiency in Children | Phase 2 | Completed | Novo Nordisk A/S | 76 | 2016-03-31 | 2026-01-16 |
A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency
somapacitan, somatropin - Adult Growth Hormone Deficiency, Growth Hormone Disorder | Phase 3 | Completed | Novo Nordisk A/S | 92 | 2015-02-12 | 2020-07-09 |
Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.
somapacitan, somatropin, placebo - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 3 | Completed | Novo Nordisk A/S | 301 | 2014-10-31 | 2020-11-23 |
Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)
No treatment given - Growth Hormone Disorder, Adult Growth Hormone Deficiency | | Completed | Novo Nordisk A/S | 98 | 2014-03-01 | 2017-01-05 |
A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency
somapacitan, somatropin - Growth Hormone Disorder, Growth Hormone Deficiency in Children | Phase 1 | Completed | Novo Nordisk A/S | 32 | 2013-12-16 | 2020-12-24 |
A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency
somapacitan, Norditropin NordiFlex® - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 1 | Completed | Novo Nordisk A/S | 35 | 2012-10-12 | 2020-12-24 |
First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects
somapacitan, placebo (somapacitan) - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 1 | Completed | Novo Nordisk A/S | 105 | 2012-01-16 | 2020-12-24 |
Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone
Norditropin NordiFlex® - Growth Hormone Disorder, Growth Hormone Deficiency in Children | | Completed | Novo Nordisk A/S | 77 | 2011-04-01 | 2014-06-24 |
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
Norditropin NordiFlex® - Growth Hormone Disorder, Growth Hormone Deficiency in Children | Phase 4 | Completed | Novo Nordisk A/S | 103 | 2010-11-01 | 2017-02-27 |
An Observational Study on Treatment Compliance by Children Treated With Growth Hormone
No treatment given - Growth Hormone Disorder, Growth Hormone Deficiency in Children | | Withdrawn | Novo Nordisk A/S | | 2010-02-01 | 2014-06-26 |
Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency
somatropin - Growth Hormone Disorder, Adult Growth Hormone Deficiency | | Completed | Novo Nordisk A/S | 387 | 2009-10-01 | 2015-01-08 |
A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone
NNC126-0083, somatropin - Growth Hormone Disorder, Growth Hormone Deficiency in Children | Phase 2 | Completed | Novo Nordisk A/S | 31 | 2009-08-01 | 2017-02-08 |
An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®
somatropin, No treatment given - Growth Hormone Disorder, Adult Growth Hormone Deficiency | | Completed | Novo Nordisk A/S | 121 | 2009-07-01 | 2015-04-29 |
Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083
NNC126-0083, placebo - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 2 | Completed | Novo Nordisk A/S | 33 | 2008-07-01 | 2017-02-08 |
Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083
NNC126-0083, placebo - Growth Hormone Disorder, Healthy | Phase 1 | Completed | Novo Nordisk A/S | 40 | 2008-07-01 | 2017-02-08 |
Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®
NNC126-0083, Norditropin® SimpleXx®, placebo - Growth Hormone Disorder, Healthy | Phase 1 | Completed | Novo Nordisk A/S | 56 | 2007-08-01 | 2017-02-09 |
Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™
NordiFlex PenMate™ - Growth Hormone Disorder, Growth Hormone Deficiency in Children | | Completed | Novo Nordisk A/S | 84 | 2007-01-01 | 2016-11-17 |
Showing 20 of 38. Sign in to see all of them.
Narrower conditions
Dwarfism, Pituitary (23) · Genetic Diseases, Inborn (6) · Turner Syndrome (6) · Renal Insufficiency, Chronic (3) · Growth Disorders (2) · Hypopituitarism (1) · Noonan Syndrome (1)
Broader conditions
Endocrine System Diseases (28) · Bone Diseases (23) · Bone Diseases, Developmental (23) · Bone Diseases, Endocrine (23) · Brain Diseases (23) · Central Nervous System Diseases (23) · Dwarfism (23) · Hypothalamic Diseases (23) · Musculoskeletal Diseases (23) · Nervous System Diseases (23) · Pituitary Diseases (23) · Hypopituitarism (22) · Cardiovascular Abnormalities (6) · Cardiovascular Diseases (6) · Chromosome Disorders (6)
Interventions
Human Growth Hormone (25) · somapacitan (9) · NNC0195-0092 (5) · NNC126-0083 (4) · Growth Hormone (2)
Sponsors
Novo Nordisk A/S (38)
Countries
Germany (12) · France (10) · Japan (9) · Sweden (8) · United States (8) · Denmark (6) · Israel (6) · Belgium (5) · United Kingdom (5) · Norway (4) · Slovenia (4) · Spain (4) · Turkey (Türkiye) (4) · Austria (3) · Switzerland (3)
Results publications
PMID 29671202, PMID 33864240, PMID 36380045, PMID 18395480, PMID 22508317, PMID 22788856, PMID 23658497, PMID 31305924, PMID 31972476, PMID 33571362, PMID 33709288, PMID 33754315, PMID 36947589, PMID 40919719, PMID 17356043, PMID 20427496, PMID 20718773, PMID 21177789, PMID 21724838, PMID 22682146, PMID 22924571, PMID 23737664, PMID 25013997, PMID 26363846, PMID 26394822, PMID 26727076, PMID 26903552, PMID 27280591, PMID 27736009, PMID 28522645, PMID 28656605, PMID 29433573, PMID 31917835, PMID 32022863, PMID 32603494, PMID 33042202, PMID 33290752, PMID 33292530, PMID 34964458, PMID 36995872, PMID 39991735, PMID 42369274
NIH funding
2008 (4), 2016 (2), 2009 (1), 2014 (1), 2015 (1)